Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia

Overview

In this study the investigators aim to test if C-reactive protein (CRP) or procalcitonin(PCT) – guided strategy allows to reduce the antibiotic use in patients wiht community-acquired pneumonia. Therefore, the safety of this intervention will be carefully measured.

Full Title of Study: “Use of Procalcitonin (PCT) and C-reactive Protein (CRP) to Guide Antibiotic Therapy in Community Acquired Pneumonia: a Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: August 2018

Detailed Description

Methods • Patients and settings: All adult (> 18 years old) patients with diagnosis community-acquired pneumonia will receive initial antibiotic therapy based on local guidelines and susceptibility patterns, according to the decision of the treating physician.Patients will be randomly assigned to one of two groups, which respectively include PCR and PCT clinical procedure protocol. Randomization will be done using a table of random numbers generated by computer. For practical reasons the doctors treating the patients in question have science group in which the patient was included. Patients included in the two groups will have baseline assessment during the first day of study: – Clinical evaluation of basic – Start of antibiotic therapy – Inclusion in the study – Randomization (after signing the Informed Consent) – Interventions: They will have circulating PCT and CRP levels measured at baseline and days 1,2,3 e 5 in both groups. Group 1 – CRP group: the duration of antibiotic therapy will be based on circulating CRP levels. Group 2 – PCT group: the duration of antibiotic therapy will be based on circulating PCT levels. Patients enrolled in the study will undergo daily measurements of plasma CRP (Dry Chemistry - Johnsons & Johnsons) and PCT (BRAHMS PCT VIDAS) levels up to day 5, and then, every 48hr in patients remaining in the ICU, and every 5 days in those transferred to the ward. Patients will be followed up 28 days, or until death or hospital transference, which comes first. PCT and CRP results will be released in sealed envelopes. During the study period, only the results corresponding to the patient randomization group will be open; i.e., CRP for CRP group patients and PCT for PCT group patients. Criteria for antibiotic interruption: The investigators will propose the interruption of antibiotics if: 1. The patients is clinically stable, without signs of active infection 2. CRP group: a relative reduction of 50% in baseline CRP levels, or a value lower than 25mg/dl is reached. 3. PCT group: a relative reduction of 90% in baseline PCT levels, or if a absolute value lower than 0.1 ng/ml is reached. The final decision regarding antibiotic therapy will be always let to the discretion of the treating physician.

Interventions

  • Other: CRP
    • C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
  • Other: PCT
    • Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy

Arms, Groups and Cohorts

  • Experimental: Group 1- C-reactive protein (CRP) guided antibiotic therapy
    • Intervention on antibiotic therapy will be based on circulating RCP levels
  • Active Comparator: Group 2 – procalcitonin (PCT) guided antibiotic therapy
    • Intervention on antibiotic therapy will be based on circulating PCT levels

Clinical Trial Outcome Measures

Primary Measures

  • Duration of antibiotic therapy for the first episode of infection
    • Time Frame: 28 days
  • Total antibiotic exposure days per 1,000 days
    • Time Frame: 28 days
  • Days alive without antibiotics
    • Time Frame: 28 days

Secondary Measures

  • All cause 28-day mortality
    • Time Frame: 28 days
  • clinical cure rate
    • Time Frame: 28 days
  • Infection relapse (diagnosed less than 48h after antibiotic discontinuation)
    • Time Frame: 28 days
  • Length of hospitalization stay
    • Time Frame: Whole hospitalization
  • In-hospital mortality
    • Time Frame: 28 days
  • Nosocomial infection rate
    • Time Frame: 28 days
  • Nosocomial superinfection (diagnosed more than 48hous after discontinuation of the antibiotic therapy given to the first episode of infection)
    • Time Frame: 28 days
  • Isolation of resistant bacteria
    • Time Frame: 28 days
  • All cause 90-day mortality
    • Time Frame: 90 days
  • costs of hospitalization
    • Time Frame: Whole hospitalization

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥ 18 years 2. Signed informed consent 3. Suspected or confirmed community-acquired pneumonia Exclusion Criteria:

1. Nosocomial pneumonia: development of symptoms after 48 hours of admission to the Emergency Department, or within 14 days after hospital discharge 2. Patients with lung cancer confirmed strongly suspected. 3. Patients with severe immunosuppression, such as severe neutropenia (<500 neutrófilos/mm3), use of corticosteroids in doses above 0.5 mg / kg / day of prednisone or equivalent for at least 2 weeks, transplantation of solid organs or cells hematopoietic, use of immunosuppressants for any other reason (eg. azathioprine or cyclosporine), hipogamagloulinemia 4. Patients with asplenia in any order 5. Pregnant 6. Patients with known HIV infection 7. Stay indicated only for social reasons 8. Patients on antibiotics for any other reason 9. Patients with multiple trauma, burns or surgery grid size in the last 5 days

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Federal University of Minas Gerais
  • Provider of Information About this Clinical Study
    • Principal Investigator: Vandack Alencar Nobre, Associate Professor, PhD – Federal University of Minas Gerais
  • Overall Official(s)
    • Vandack A Nobre, PhD, Principal Investigator, Medical School of the Federal University of Minas Gerais
    • Karla F Finotti, MD, Study Chair, Medical School of the Federal University of Minas Gerais

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.